Approved January 1998
Cancer & Oncology
Proleukin (aldesleukin) has been approved for treating adult patients with metastatic melanoma.
In clinical trials of the drug, 16% of 270 patients responded to the drug with half of the patients remaining alive for four years after treatment. Proleukin produced a complete response in 6% of the 270 patients. Approximately 60% of the 17 patients who achieved a complete response have remained in remission for greater that five years without further treatment.
Adverse events reported include capillary leak syndrome, flu-like symptoms, and serious toxicities, including low blood pressure, decreased kidney and lung function, respiratory distress, cardiac abnormalities, changes in mental status and edema.
Proleukin is an injectable, recombinant form of interleukin-2.
The Proleukin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.